Nothing Special   »   [go: up one dir, main page]

Risitano, 2013 - Google Patents

Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

Risitano, 2013

Document ID
1979253973527773261
Author
Risitano A
Publication year
Publication venue
Complement Therapeutics

External Links

Snippet

Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder characterized by complement-mediated hemolytic anemia, thrombophilia, and bone marrow failure. PNH is due to a somatic, acquired mutation in the X-linked phosphatidylinositol glycan class A (PIG …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Risitano Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies
Risitano Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
Brodsky Paroxysmal nocturnal hemoglobinuria
Risitano et al. Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents
Pu et al. Paroxysmal nocturnal hemoglobinuria from bench to bedside
Liszewski et al. Complement dysregulation and disease: insights from contemporary genetics
Mathern et al. Molecules great and small: the complement system
Risitano et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization
Zhou et al. The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis
Ecker et al. Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
Clarke et al. Complement modulation of T cell immune responses during homeostasis and disease
Kimura et al. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement
Waterborg et al. Protective role of the MER tyrosine kinase via efferocytosis in rheumatoid arthritis models
Momi et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo
Choi et al. Mst1-FoxO signaling protects Naive T lymphocytes from cellular oxidative stress in mice
Uche et al. PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt
Kimura et al. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury
Schubert et al. Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease
Bandini et al. The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis
Wang et al. Significance of glycosylphosphatidylinositol-anchored protein enrichment in lipid rafts for the control of autoimmunity
Risitano Anti-complement treatment in paroxysmal nocturnal hemoglobinuria: where we stand and where we are going
Omar et al. Schlafen2 mutation unravels a role for chronic ER stress in the loss of T cell quiescence
Liu et al. Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice
Risitano Paroxysmal nocturnal hemoglobinuria
US20170196994A1 (en) Models of thrombotic thrombocytopenic purpura and methods of use thereof